Results 171 to 180 of about 20,086,433 (308)
Neutrophil Extracellular Traps in Central Nervous System Diseases. [PDF]
Zhu J, Zhu H, Hou W, Liu JY.
europepmc +1 more source
ABSTRACT Objective Progression independent of relapse activity is a major determinant of long‐term disability in multiple sclerosis, but its immunopathologic basis remains incompletely understood. We investigated whether relapse‐independent progression in radiologically stable relapsing–remitting multiple sclerosis is associated with distinct ...
Antonio Bruno +19 more
wiley +1 more source
Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology. [PDF]
Gould TD, Mathew SJ, Fava M, Shekhar A.
europepmc +1 more source
Essential Clinical Anatomy of the Nervous System [1st Ed.]
A clear and succinct presentation of the underlying anatomy of the nervous system, with directly related applications of the anatomy to clinical ...
Rea, Paul
core
ABSTRACT Gliomas have undergone a profound redefinition over the past decade, transitioning from morphology‐based entities to biologically coherent diseases defined by molecular alterations. The 2021 WHO Classification of Tumors of the Central Nervous System and its 2022 update formalize this shift, establishing integrated diagnosis as the global ...
Maria Guarnaccia, Sebastiano Cavallaro
wiley +1 more source
Association of physical activity volume with the risks of nervous system diseases: a retrospective cohort study. [PDF]
Ye M, Zhu Y, Xu K, Li L, Hu F.
europepmc +1 more source
Endothelial Cell Proteins as Biomarkers in Susac Syndrome
ABSTRACT Objective Susac syndrome (SS) is a rare CD8+ T cell–mediated microangiopathy affecting the brain, retina, and auditory labyrinth. Endothelial injury is thought to be a central mechanism; however, no circulating disease biomarkers are known. We performed targeted proteomic profiling to identify circulating endothelial‐associated proteins as ...
Rohit Benjamin +11 more
wiley +1 more source
New insights into disease-modifying factors and clinical translation for central nervous system diseases. [PDF]
Li S, Ji X, Walczak P, Boltze J.
europepmc +1 more source
Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui +10 more
wiley +1 more source

